100 results about "Desamethasone" patented technology

The invention belongs to the technical field of biology, and particularly relates to milk-derived pentapeptide for promoting calcium mineral absorption and application of the milk-derived pentapeptide. The CPP containing the high-activity peptide fragment is obtained by optimizing a process, and the influence of the CPP on mineral absorption is verified by utilizing a zebra fish model. Then, the pentapeptide GPFPI with calcium absorption promoting activity is screened out from the CPP in combination with peptidomics and a molecular docking technology, functional verification is carried out, it is found that the pentapeptide presents a dose-dependent trend on Ca < 2 + > transport, the Ca < 2 + > transport amount is remarkably increased by 23.23% at 10 mu M, and meanwhile, zebra fish experiments show that intervention of the GPFPI effectively reverses accumulated optical density value reduction caused by dexamethasone, and the effect of inhibiting calcium absorption is achieved. Compared with a manufacturing module, the skull accumulative optical density value of a GPFPI (2-20 mu M) processing group is remarkably increased. It is shown that the synthetic peptide GPFPI can effectively promote Ca < 2 + > transfer and absorption, improve the osteoporosis symptom of zebra fish and increase deposition of calcium in bones.

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.

The invention relates to betulinic acid type saponin derivatives as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The structural general formula of the betulinic acid type saponin derivative is # imgabs0, R1 is selected from hydroxyl or-O-G, and G is monosaccharide; r2 is selected from dopamine, 5-aminovaleric acid, 4-aminobutyric acid or 3-aminopropionic acid and the like and salts thereof. The betulinic acid type saponin derivative does not show obvious cytotoxicity to THP-1 macrophages, and can obviously reduce the release of IL-6 and IL-1beta in the THP-1 macrophages induced by LPS (lipopolysaccharide). Compared with betulinic acid and positive control medicine mesalazine, the pharmaceutical composition has better anti-inflammatory activity, has the treatment effect of improving diarrhea and hemafecia of mice with colitis remarkably superior to those of betulinic acid and positive control medicine mesalazine, has the treatment effect of dermatitis superior to that of positive control medicine dexamethasone, and does not have obvious toxic or side effects such as weight loss and immunosuppression. Therefore, the betulinic acid type saponin derivative has good in-vivo and in-vitro safety and druggability.

The invention provides an osteogenic induced differentiation kit, a culture medium and a preparation method of the culture medium, and particularly relates to the technical field of stem cells. The kit comprises a DMEM (dulbecco's modified eagle medium) basal culture medium, fetal calf serum, dexamethasone, vitamin C, beta-glycerol phosphate, mesenchymal stem cell osteogenesis induced supernatant, alizarin red S staining solution and acetic acid. According to the kit provided by the invention, the problems of slow calcium nodule formation, small calcium nodule quantity and small calcium nodule in the osteogenic induced differentiation of the umbilical cord mesenchymal stem cells in the prior art are solved, so that the calcium nodule formation of the umbilical cord mesenchymal stem cells is effectively promoted, meanwhile, the calcium nodule quantity can be increased, and the osteogenic induced differentiation period is shortened.

The invention belongs to the technical field of biology, and particularly relates to casein source heptapeptide for promoting calcium absorption and utilization and application of the casein source heptapeptide. The CPP containing the high-activity peptide fragment is obtained through an optimization process, and the influence of the CPP on mineral absorption and conversion is evaluated by utilizing a mineral deficiency rat model; then, heptapeptide with calcium absorption promoting activity is screened out from the CPP in combination with peptiomics and molecular docking technologies, functional verification is carried out, it is found that when the VAPFPEV is 2 mu M, the Ca < 2 + > transport amount is remarkably increased by 25.25%, meanwhile, zebra fish experiments show that intervention of the VAPFPEV effectively reverses reduction of an accumulated optical density value caused by dexamethasone, and compared with a module making set, the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the The skull accumulative optical density value of a VAPFPEV (1-20 [mu] M) processing group is obviously increased. It is shown that VAPFPEV can effectively promote Ca < 2 + > transfer and absorption, improve the osteoporosis symptom of zebra fish and increase deposition of calcium in bones.

The invention discloses a steroid hormone degrading bacterium as well as a screening method and application thereof, and relates to the field of biological medicines, the steroid hormone degrading bacterium comprises klebsiella pneumoniae (KP2022 Klebsiella pneumoniae) with the preservation number of CCTCC (China Center for Type Culture Collection) NO: M2025478. The steroid hormone degrading bacterium provided by the invention has the capability of efficiently degrading dexamethasone, is beneficial to degrading dexamethasone in the environment, is conveniently obtained by adopting a screening method, and provides a sample for research on degradation of steroid hormones.

The invention relates to a dexamethasone sodium phosphate injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: 1, sequentially adding glycerol, edetate disodium and dexamethasone sodium phosphate into water for injection according to a weight ratio of (20-25): (0.08-0.12): (4-6), mixing and dissolving, and introducing nitrogen until the dissolved oxygen content is less than or equal to 1mg / L to obtain a liquid medicine 1; step 2, adding a pH regulator into the liquid medicine 1 to regulate the pH value to 7.0-8.5 to obtain liquid medicine 2; and step 3, filtering, filling and sealing the liquid medicine 2, and controlling the residual oxygen content to be less than or equal to 5% to obtain the dexamethasone sodium phosphate injection. Wherein the whole preparation process is protected by inert gas. According to the preparation method of the dexamethasone sodium phosphate injection provided by the invention, the prescription composition of an original drug does not need to be changed, and the prepared dexamethasone sodium phosphate injection can be stably stored at room temperature by adjusting a specific pH range, keeping filling of an inactive gas until the dissolved oxygen content is less than or equal to 1mg / L in the whole preparation process and controlling the residual oxygen content to be less than or equal to 5%.

The invention discloses oyster pallium hexapeptide with an effect of promoting osteogenesis as well as a preparation method and application of the oyster pallium hexapeptide. The amino acid sequence of the oyster pallium hexapeptide is Phe-Phe-Glu-Pro-Lys-Phe. Fresh oyster mantle is used as a raw material, pepsin and trypsin are used for hydrolysis and centrifugation to obtain supernate, then ultrafiltration is carried out to obtain filtrate with the molecular weight being 1000 Da or below, finally freeze drying is carried out, the sequence of oyster hydrolytic peptide is obtained through mass spectrum identification, and by means of a molecular docking technology and a database prediction simulation method, the oyster hydrolytic peptide is obtained. Oyster peptide with high osteogenesis promoting capacity is screened from a plurality of peptide sequences. The oyster hexapeptide obtained by the invention has the effects of improving osteoblast proliferation and differentiation capacity and improving dexamethasone-induced zebra fish bone loss, and can be used as a beneficial dietary supplement in related products for delaying bone loss.

A pharmaceutical composition is provided. The pharmaceutical composition includes dexamethasone at a concentration of at least 400 picomolar and up to 20 millimolar and decanoic acid at a concentration of at least 10 micromolar and up to 5 millimolar. In some embodiments, the pharmaceutical composition is used to treat osteoarthritis.

Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and / or thymus weight loss in a mouse are disclosed as well as uses thereof.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

The application discloses a construction method and application of an osteoarthritis cartilage organoid, and the method comprises the following steps: 1) mesenchymal stem cells are inoculated on a round bottom culture plate by a Micromass method, and are cultured in a chondrogenic induction culture medium containing dexamethasone, ascorbic acid and TGF-beta 3 for 10-18 days to form a transparent cartilage organoid; and 2) the transparent cartilage organoid is placed in an osteoarthritis induction culture medium containing dexamethasone, L-thyroxine, inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and beta-glycerophosphate sodium for continuous culture for 5-10 days to obtain an osteoarthritis cartilage organoid; the model simultaneously presents multi-dimensional pathological characteristics such as matrix degeneration, hypertrophy, inflammation activation and vascularization trend, and can be used for osteoarthritis pathogenesis research, drug screening and cell treatment effect evaluation; the construction method is controllable and has good repeatability, and provides a reliable three-dimensional in-vitro model for osteoarthritis research.

This invention discloses a heterozygous sesquiterpene tricyclic epoxy compound derived from the strain *Arthrum oligosporum*, its preparation method, and its applications, belonging to the field of natural product chemistry. This invention provides a heterozygous sesquiterpene tricyclic epoxy compound derived from *Arthrum oligosporum* (… A.oligospora ) AOL_ s00210g57 Anthrobotrisin D, a novel heterozygous sesquiterpene tricyclic epoxy compound from a gene knockout strain, has been shown in vitro to possess excellent anti-inflammatory activity, significantly inhibiting lipopolysaccharide-induced inflammatory responses in mouse microglia. It exhibits a clear dose-dependent inhibitory trend at multiple levels, including NO release, protein and mRNA expression of inflammatory factors (TNF-α, IL-1β, IL-6), and iNOS protein and mRNA expression. Furthermore, at a concentration of 33 μM, its anti-inflammatory effect is comparable to that of the clinically proven positive drug dexamethasone, and in some aspects, it is even superior. This invention not only provides a new lead compound for the development of anti-inflammatory drugs but also opens up new directions for developing new drugs from the unique microbial resource of nematode-preying fungi.

The invention discloses a pharmaceutical composition for preventing esophageal stenosis. The pharmaceutical composition consists of glucocorticoid and sesame oil, the glucocorticoid is triamcinolone acetonide or dexamethasone. The pharmaceutical composition provided by the invention is prepared from 1-5 parts by weight of triamcinolone acetonide and 10-15 parts by weight of sesame oil; or 5-10 parts by weight of dexamethasone and 100 parts by weight of sesame oil. The medicine composition is simple, raw materials are low in price, and mass production and use are facilitated. Practical research finds that the pharmaceutical composition provided by the invention can be used for preventing esophageal stenosis caused by disease reasons, such as esophageal stenosis after large-area endoscopic submucosal dissection (the dissection area is 2 / 3 or above) of esophageal premature cancer, esophageal restenosis after benign esophageal stenosis dilation treatment and the like.

To provide a method for manufacturing a hepatoblast, a hepatoblast, and a method for manufacturing a hepatocyte.SOLUTION: A method for manufacturing a hepatoblast includes a step of culturing an iPS cell-derived entodermal cell serum-free medium containing FGF2, HGF, oncostatin M and dexamethasone and differentiating the cell into a hepatoblast. As one aspect, the medium further contains nicotinamide, or the serum-free medium is serum-free differentiation medium, or an iPS cell is derived from a human, or a culture period of the iPS cell-derived entodermal cell is 5 days or more and less than 10 days.SELECTED DRAWING: Figure 2-1

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

The invention relates to the technical field of perovskite thin films, in particular to a preparation method of a fluorine-containing steroid molecule regulated perovskite thin film, the perovskite thin film and a photovoltaic device.The perovskite thin film comprises a precursor composition, the precursor composition is a perovskite precursor salt solution, and the perovskite precursor salt solution is composed of precursor salt, a solvent system and fluorine-containing steroid molecules Dex, the precursor salt is Cs0.05 (FA0.95 MA0.05) 0.95 Pb (I0.95 BT0.05) 3, the precursor salt comprises FAI, PbI2, MACl, PbBr2, CsI and MABr, the fluorine-containing steroid molecule Dex has a steroid ring rigid skeleton and simultaneously contains = O,-OH and C-F functional sites, the fluorine-containing steroid molecule Dex is preferably dexamethasone Dex, and the fluorine-containing steroid molecule Dex is replaced by prednisolone, triamcinolone acetonide and flumetasone; the solvent system is composed of DMP and NMP, the volume ratio of DMP to NMP is 4: 1, and the solvent system contains an organic solvent. The semitransparent perovskite thin film prepared by the invention has high transmittance and excellent crystallization quality, and the open-circuit voltage, the fill factor and the operation and storage stability of a prepared device are remarkably improved.

This invention discloses a sodium alginate cross-linked matrix metalloproteinase-sensitive peptide-loaded dexamethasone sodium phosphate hydrogel and its preparation method. The dexamethasone-loaded hydrogel has good injectability. After injection, it is cleaved by MMPs at the site of inflammation in an inflammatory environment to release dexamethasone, exhibiting good sustained-release effect. It achieves targeted and long-acting treatment of inflammatory arthritis, osteoarthritis or other inflammatory diseases, and reduces the frequency of repeated intra-articular injections of glucocorticoids.

The invention discloses application of deaminotyrosine in improvement or prevention and treatment of muscular atrophy, and relates to the technical field of biological medicines. The invention finds that in the cellular level, DAT can effectively resist C2C12 myoblast senescence induced by etoposide; in a dexamethasone-induced C2C12 myotube atrophy model, DAT not only inhibits myotube diameter reduction from the form, but also down-regulates mRNA expression of key atrophy genes Atrogin-1 and MuRF-1 from the molecular level, and inhibits excessive activation of a ubiquitin-proteasome system; in-vivo animal experiments prove that DAT can reverse aging-related dyskinesia of rapidly-aged SAMP8 mice, and gait parameters of the rapidly-aged SAMP8 mice are all remarkably improved. According to the invention, a complete evidence chain from cells to the whole is constructed, and the DAT is proved to improve the senescent skeletal muscle atrophy through multiple ways of intervening cell senescence, antagonizing protein degradation, improving muscle microenvironment and the like, and shows important potential application value.

Provided are mixtures of dexamethasone-N-methacryloylglycylglycyl hydrazide (MA-Gly-Gly-NHN=Dex) monomers enriched in a desired diastereomer, and polymer compositions of same. Also provided are methods of treating inflammatory conditions such as arthritis that use the polymer compositions.

The present invention discloses a use of a Gastrodia elata-derived compound for alleviating a sarcopenia phenotype. The Gastrodia elata-derived compound can effectively alleviate a sarcopenia phenotype caused by dexamethasone modeling and can be used to prevent sarcopenia.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

The invention provides the dexamethasone sodium phosphate photodegradation impurity as well as the preparation method and the detection method thereof, so that the blank in the research aspect of the dexamethasone sodium phosphate photodegradation impurity is filled, and the process research and the quality control of dexamethasone sodium phosphate raw material medicines and preparations are facilitated; the method has an important practical value for controlling the product quality of dexamethasone sodium phosphate.

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

The invention provides an umbilical cord mesenchymal stem cell osteogenesis induced differentiation culture medium and a preparation and induction method, and particularly relates to the technical field of stem cells. The culture medium comprises a Dulbecco's Modified Eagle Medium (DMEM) basal culture medium, and further comprises the following components in concentration or proportion: 5-15% by volume of fetal calf serum, 0.1-10 [mu] M of dexamethasone, 10-450 [mu] g / ml of vitamin C, 2-80 mM of beta-glycerol phosphate, and 10-250 [mu] g / ml of tricalcium silicate doped with magnesium, zirconium and zinc ion components. According to the umbilical cord mesenchymal stem cell osteogenic induction differentiation culture medium provided by the invention, the problems of slow calcium nodule formation, small calcium nodule quantity and small calcium nodule in the osteogenic induction differentiation of umbilical cord mesenchymal stem cells in the prior art are solved, so that the calcium nodule formation of the umbilical cord mesenchymal stem cells is effectively promoted, meanwhile, the calcium nodule quantity can be increased, and the survival rate of the umbilical cord mesenchymal stem cells is increased. And the osteogenic induced differentiation period is shortened.

The invention belongs to the technical field of medicines, discloses a synergistic pharmaceutical composition based on pulsatilla saponin and bifendate and application of the synergistic pharmaceutical composition in treatment of acute liver injury, and particularly discloses a pharmaceutical composition which comprises pulsatilla saponin B4 and bifendate or dexamethasone. The invention provides a pharmaceutical composition containing pulsatilla saponin B4 (BS-B4) and a drug bifendate or dexamethasone combined with the pulsatilla saponin B4, and experiments prove that the pharmaceutical composition has good effects of preventing and treating acute liver injury and can effectively reduce spleen and liver indexes and expression of serum liver injury markers (ALT, AST and T-Bil-V). The pharmaceutical composition can be used for effectively relieving acute liver injury induced by carbon tetrachloride by regulating inflammatory factors (IL-1beta, TNF-alpha and IL-10) and oxidative stress pathways (MDA and GSH-Px).

The present invention discloses a trimer of Cys-Thr-Glu, namely [Cys-Thr-Glu]<subgt;3< / subgt;, and discloses its preparation method and therapeutic effect on testes damaged by dexamethasone. Experiments prove that [Cys-Thr-Glu]<subgt;3< / subgt; of the present invention can not only effectively treat testes damaged by dexamethasone, but also has a significantly stronger therapeutic effect on testes damaged by dexamethasone than the therapeutic effect of Cys-Thr-Glu on testes damaged by dexamethasone. Therefore, it is proposed that the present invention provides an effective technical means for treating testes damaged by dexamethasone.

The present invention provides a preparation method of tetraene acetate and its derivatives, comprising the following steps: subjecting a compound I to an isocyano compound to an addition reaction, followed by dehydration to obtain a compound II, subjecting the compound II to a cyclization reaction with formaldehyde under the action of a strong base, subjecting the compound II to a hydrolysis and elimination reaction in an acidic solution to obtain a compound III, and subjecting the compound III to esterification to obtain the tetraene acetate and its derivative IV. Compared with the existing preparation method for synthesizing tetraene acetate using compound I as a raw material, the present invention obtains the product through isocyanation, cyclization, hydrolysis, and esterification reactions. The reagents used are cheap and readily available, no precious metals are used, the reaction conditions are simple, the process operation is simple, and the method is suitable for large-scale industrial production. After purification, the total yield is greater than 80%, and the purity is greater than 98%. The obtained tetraene acetate and its derivatives can be used to synthesize steroid drugs such as dexamethasone and betamethasone.

The invention discloses a bone marrow mesenchymal stem cell osteogenesis induction enhancing solution, which is prepared from the following components: 6.5 to 9.5 mg / ml of sodium hydrosulfite, 8.5 to 13.5 mg / ml of nicotinamide ribose, 1.5 to 2.1 mg / ml of deoxycholic acid, 45.0 to 55.0 mu g / ml of estradiol, 0.2 to 0.6 mg / ml of calcitriol, and 90.0 to 110.0 mu g / ml of rrBMP-2. Traditional osteogenic induction and 1% osteogenic induction enhancing liquid have high cell activity on BMSC cell proliferation, and compared with traditional osteogenic induction (containing 0.2 mmol / L of ascorbic acid, 10 mmol / L of beta-sodium glycerophosphate and 100 nmol / L of dexamethasone), the alkaline phosphatase staining color is deeper, the positive area is larger, the alkaline phosphatase activity is higher, more calcium nodules are formed, and the BMSC cell proliferation effect is better. It is shown that the osteogenic induction enhancing liquid provided by the invention enhances the osteogenic ability of the rat BMSC.